ERBB2 and cancer: Currently, CD133, HER2, and EpCAM-directed CAR-T cells were proved to lyse CSCs in vitro and in vivo [43–45], indicating that the strategy of using CAR-T cells to eliminate CSCs could be a promising treatment for cancers.